OMEROS CORP (OMER)
Health Care · Biotechnology · NASDAQ
A biopharmaceutical company bridging commercial success from its ocular surgery product with a clinical-stage pipeline targeting complement-mediated disorders.
What OMEROS CORP does
Omeros Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing small-molecule and protein therapeutics. Its business model includes marketing OMIDRIA (phenylephrine and ketorolac injection) for use during cataract surgery or intraocular lens replacement, while advancing a pipeline of candidates targeting complement-mediated diseases.
Themes: ophthalmology, complement-mediated diseases, rare diseases
Fundamentals
- Price$19.12 as of 2026-10-08 close
- Market cap$1.4B as of 2026-08-07 (share count; price 2026-10-08)
- 1-year return+335.5% 2025-10-08 close $4.39 → 2026-10-08 close $19.12
- P/E20.32 as of 2026-10-08
- Debt / equity21.55 as of 2026-09-02
- Revenue CAGR (3y)+4.4% SEC XBRL
- Beta1.29 as of 2026-09-02
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How OMER compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How OMEROS CORP looks technically
OMEROS CORP (OMER) is trading 45.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 35 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative). It made a new 20-day high about 13 trading days ago.
Trend
7
| Distance from the 200-day | it is trading 45.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +45.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $17.56 | $17.56 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $13.18 | $13.18 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 35 trading days ago — a "golden cross", a bullish long-term signal | 35 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend) | 21.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30) | 54.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($17.82 to $21.24) — its "stochastic" reading is 38 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 38.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $21.24 | $21.24 |
|---|---|---|
| From the 52-week high | it is 10.0% below its 52-week high (its highest price of the past year) | -10.0% |
| Above the 52-week low | it is 370.9% above its 52-week low (its lowest price of the past year) | +370.9% |
| Below the 52-week high | it is 10.0% below its highest point of the past year | 10.0% |
| Since a 20-day breakout | it made a new 20-day high about 13 trading days ago | 13 sessions |
| Since a 55-day breakout | it made a new 55-day high about 13 trading days ago | 13 sessions |
| All-time high | its highest closing price on record is $30.23 (set on 2015-08-18) | $30.23 |
| Given back of the 52-week move | over the past year its closes ranged ($4.10 to $21.05), and it has given back only a small part of its rise from last year’s low — 11% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $10.03 to $10.57. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 11.4% |
| From the all-time high | it is 36.8% below its all-time high | -36.8% |
| Nearest price level | it is trading 2.5% below a resistance level at $19.60 — a price it turned at twice since 2026-08-25, most recently on 2026-09-09. Since 2024-10-08 it has 12 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.5% |
| All-time low | its lowest closing price on record is $0.92 (set on 2023-10-16) | $0.92 |
| Above the all-time low | it is 1978.3% above its all-time low | +1,978% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 76% of it) | 24th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.8224 between its high and its low — about 4.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.8224 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $16.80 and $20.91 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $16.80 – $18.86 – $20.91 |
| Typical daily range (% of price) | its price moves about 4.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.3% |
| Stretch from the 200-day average | it is trading 7.2 daily ranges above its 200-day average price (45.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.64× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.6% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.6% |
|---|---|---|
| Open gap | it gapped 23.0% above the previous close 39 sessions ago and has not traded back through the level it left behind at 13.71 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +23.0% |
| Gap filled | a 2.2% gap down opened on 2026-10-07 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +3.3% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 1.0 percentage points (the stock gained 0.0% while the market gained 1.0%) | -1.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 82.9 percentage points (the stock gained 86.7% while the market gained 3.8%) | +82.9% |
| vs market, 6 months | over the past 6 months this stock beat the market by 58.2 percentage points (the stock gained 75.7% while the market gained 17.5%) | +58.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 320.6 percentage points (the stock gained 335.5% while the market gained 15.0%) | +320.6% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 13% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 18.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +12.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 44% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $13.28 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +44.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-12 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $18.23 — a volume-weighted average of daily closes over 41 sessions, not a true tick-by-tick VWAP. | +4.8% |
Price levels it has turned at before
OMER last closed at $19.12 on 2026-10-08. Since 2024-10-08 it has turned at 12 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $19.60 | Resistance | 2.5% above the last close | turned there twice · 2026-08-25 to 2026-09-09 |
| $12.57 | Support | 34.3% below the last close | turned there four times · 2024-11-26 to 2026-02-17 |
| $12.04 | Support | 37.0% below the last close | turned there twice · 2025-10-15 to 2026-03-11 |
| $10.62 | Support | 44.5% below the last close | turned there twice · 2026-02-05 to 2026-07-08 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · beating the market · Stretched far above its 200-day average (6+ daily ranges) · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.67 mean, 1=Strong Buy…5=Strong Sell) — 2 analysts
- Mean price target$27.50 range $22.00 – $33.00
Analyst estimates, as of 2026-10-04. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for OMER
- Consensus EPS estimate-$0.02 next reporting period, as of 2026-10-04
- Estimate change, 30 days+$0.005 from -$0.025, on 2026-08-30, 35-day window
- Readings revised upward29% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant accumulated deficit and potential need for additional financing to fund operations and R&D.","Dependence on a single commercial product (OMIDRIA) for revenue.","Complex financial instruments and debt obligations that may cause volatility in net income due to non-cash fair value adjustments."]
What changed in the latest 10-Q
AI-assisted comparison of OMER's 10-Q filed 2026-05-13 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Company described as 'innovative, commercial-stage biotechnology company' in newer filing (2026-05-13) vs. 'clinical-stage biopharmaceutical company' in older filing (2025-11-13)
- YARTEMLEA FDA approval on December 23, 2025 and commercial availability in U.S. for TA-TMA treatment (newer filing)
- Commercial distribution and sales of YARTEMLEA began January 2026 (newer filing)
- 30 unique accounts had ordered YARTEMLEA by March 31, 2026 (newer filing)
- Field force deployment details: account managers, directors, market development managers, access leads, and medical science liaisons detailing all 175 transplant centers (newer filing)
- Four primary launch objectives for YARTEMLEA commercialization detailed in newer filing
- YARTEMLEA has no boxed warning and no REMS requirement (newer filing)
- MAA for YARTEMLEA submitted to EMA under centralized review procedure (newer filing)
- European Commission granted orphan medicinal product designation for narsoplimab in HSCT (newer filing)
- Evaluation of partnerships for YARTEMLEA commercialization outside U.S. (newer filing)
- Reference to 10-K for year ended December 31, 2025 filed March 31, 2026 (newer filing vs. 2024 in older)
- Removed:
- Reference to BLA resubmission in March 2025 and PDUFA target action dates of September 25 and December 26, 2025 (removed in newer filing)
- Reference to FDA extending PDUFA date and expectation of FDA meeting the date (removed in newer filing)
- Statement that 'All analyses requested by FDA...have been consistent with and have provided statistically significant support' (removed in newer filing)
- Reference to MAA submission in June 2025 and EMA validation (removed in newer filing)
- Statement 'We expect an opinion on the MAA in mid-2026' (removed in newer filing)
- Reference to pause of OMS1029 and MASP-2 small-molecule development in Q1 2025 to preserve capital (removed in newer filing)
- Alternative Pathway / MASP-3 section describing zaltenibart development programs in PNH and C3G (removed in newer filing)
- Details on Phase 2 clinical trials and open label extension study for zaltenibart (removed in newer filing)
- October 10, 2025 APLA announcement with Novo Nordisk and expected Q4 2025 closing (removed in newer filing)
- Post-closing restrictions on exploitation of MASP-3 and alternative pathway products (removed in newer filing)
- Retention of MASP-3 small-molecule program and 'grandfathered' MASP-3 antibodies rights (removed in newer filing)
- PDE7 Inhibitor Programs section begins but is truncated in both versions
- Reworded:
- MASP-2 section heading changed from 'Lectin Pathway / MASP 2' to 'Lectin Pathway / MASP-2' (formatting)
- 'antigen-antibody complex-dependent classical complement activation pathway' changed to 'antibody-dependent classical complement activation pathway' (newer filing)
- Narsoplimab described as 'lead product and product candidate' in newer vs. 'lead product candidate' in older filing
- Added 'YARTEMLEA ® (narsoplimab-wuug)' brand name and product designation in newer filing
- Clinical development framing changed from pending approval to post-approval label expansion efforts (newer filing)
- Notes:
- The newer filing's MD&A section appears truncated at the end ('Sale of Zaltenibart / MASP-3' section incomplete), limiting full comparison of Alternative Pathway and PDE7 sections
- Older filing's PDE7 section is also truncated, preventing complete comparison of that program description
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 11 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 2 sells ($419000) — 1 selling insider
- Last 90 days · read to 2026-10-040 buys · 11 sells ($2M) — 4 selling insiders
- Last 180 days · read to 2026-10-040 buys · 12 sells ($2M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-23. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about OMER's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding OMER as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 10,040,170
- Reported value $95,482,013
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about OMER's institutional holders → See what each manager we track holds →
Short interest (FINRA)
OMER had 12,491,576 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
OMER had 17.3% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.31 days to cover at the same settlement.
- Reported short interest (shares) 12,491,576
- Short interest (% of shares outstanding) 17.3%
- Prior settlement (shares) 12,758,406
- Reported change -2.09%
- Days to cover (reported) 9.31
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Alnylam Pharmaceuticals (ALNY)
- Alexion Pharmaceuticals (subsidiary of AstraZeneca) (AZN)
- Apellis Pharmaceuticals (APLS)
- Regeneron Pharmaceuticals (REGN)
- Novartis (NVS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare OMER vs…
OMEROS CORP is found in…
OMER ranks in…
Frequently asked questions
What does OMEROS CORP (OMER) do?
Omeros Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing small-molecule and protein therapeutics. Its business model includes marketing OMIDRIA (phenylephrine and ketorolac injection) for use during cataract surgery or intraocular lens replacement, while advancing a pipeline of candidates targeting complement-mediated diseases.
What sector is OMEROS CORP (OMER) in?
OMEROS CORP (OMER) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are OMEROS CORP's (OMER) competitors?
Notable peers of OMEROS CORP (OMER) include Alnylam Pharmaceuticals, Alexion Pharmaceuticals (subsidiary of AstraZeneca), Apellis Pharmaceuticals, Regeneron Pharmaceuticals and Novartis. This peer set is informational only — not financial advice.
Is OMEROS CORP (OMER) overbought or oversold right now?
OMEROS CORP (OMER) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 55, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on OMER come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.